Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.58 |
| ▸ | SLC22A12 | Q96S37 | 11/20 | 0.54 |
| ▸ | PLA2G7 | Q13093 | 6/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3363248 | 0.82 | SLC6A4 (0.58) | — | |
| SCHEMBL3364476 | 0.82 | SLC6A4 (0.69) | — | |
| SCHEMBL7741483 | 0.82 | SLC6A4 (0.65) | SLC22A12PLA2G7 | |
| SCHEMBL28204660 | 0.75 | SCN9A (0.57) | SCN9A | |
| SCHEMBL3477410 | 0.73 | SCN9A (1.00) | SCN9A | |
| SCHEMBL7737215 | 0.73 | SLC6A4 (0.68) | — | |
| SCHEMBL28678270 | 0.73 | PLA2G7 (0.89) | PLA2G7 | |
| SCHEMBL7207970 | 0.73 | SLC6A4 (0.49) | SLC22A12PLA2G7 | |
| SCHEMBL7741395 | 0.73 | SLC6A4 (0.67) | — | |
| SCHEMBL16177668 | 0.71 | SLC22A12 (0.78) | SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | SCN9A 2922/4885SLC22A12 4002/4885PLA2G7 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.